<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701205</url>
  </required_header>
  <id_info>
    <org_study_id>QRSTPP</org_study_id>
    <nct_id>NCT02701205</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Celgen Bio-Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Celgen Bio-Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy&#xD;
      and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in&#xD;
      the treatment of Moderate to Severe Plaque Psoriasis. The primary purpose is to assess the&#xD;
      different maintaining treatment programme in Moderate to Severe plaque psoriasis by Qiangke®.&#xD;
      And the second purpose is to assess the efficacy and safety of Qiangke® in Moderate to Severe&#xD;
      Plaque Psoriasis. The trial will include 216 Moderate to Severe plaque psoriasis patients,and&#xD;
      at the first stage they will be randomized divided into three group: full-dose of Qiangke®&#xD;
      group, half-dose of Qiangke® group and placebo group.And the blind stage will last for 12&#xD;
      weeks. Then at the second stage, all patients will receive 50mg qw of Qiangke® for additional&#xD;
      12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic inflammatory skin disease that can lead to significant physical and&#xD;
      psychologic distress for patients.Recombinant Human TNF Receptor-Ig Fusion Protein for&#xD;
      Injection (Qiangke®) can block the role of the cytokine tumor necrosis factor (TNF)-alpha.&#xD;
&#xD;
      TNF-α plays a major role in the pathophysiology of both Psoriasis（PsO）and Psoriatic Arthritis&#xD;
      (PsA). TNF-α levels are elevated in psoriatic skin lesions, serum samples, and synovial&#xD;
      fluid. Anti-TNF-α therapy has shown efficacy in treating psoriatic skin lesions, joint pain&#xD;
      and swelling, enthesitis, and dactylitis plus the ability to improve mobility, reduce&#xD;
      radiographic progression of disease, and influence quality of life parameters.&#xD;
&#xD;
      Qiangke® is a dimeric, soluble fusion protein consisting of the extracellular ligand binding&#xD;
      portion of the TNF receptor linked to the Fc portion of human Immunoglobulin gamma-1（IgG1）.&#xD;
      It is capable of binding and neutralizing soluble TNF and transmembrane TNF. It alters&#xD;
      neutrophil migration and dendritic cell and T-cell maturation and migration, thus decreasing&#xD;
      the local and systemic production of pro-inflammatory cytokines and their subsequent effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 90 &amp; 50</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PASI 90 &amp; 50 &amp; 75</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA)</measure>
    <time_frame>Week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment (PGA)</measure>
    <time_frame>Week 12 &amp; 24</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety parameters - Number of Participants With Abnormal Laboratory Values and/or Adverse Events</measure>
    <time_frame>Week 12 &amp; 24</time_frame>
    <description>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Plaque Psoriasis</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etanercept (half dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.</description>
    <arm_group_label>etanercept</arm_group_label>
    <other_name>Qiangke®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept (half dose)</intervention_name>
    <description>Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.</description>
    <arm_group_label>etanercept (half dose)</arm_group_label>
    <other_name>Qiangke®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, age 18-65,Asian.&#xD;
&#xD;
          2. Freely provides both verbal and written informed consent.&#xD;
&#xD;
          3. Consent to use effective contraception during the trial period.&#xD;
&#xD;
          4. Participant had a clinical diagnosis of psoriasis for at least 6 months, and had&#xD;
             moderate to severe plaque psoriasis&#xD;
&#xD;
          5. Participant must have a Psoriasis Area Severity Index score greater than or equal to&#xD;
             12 at the baseline visit and Body Surface Area involvement greater than or equal to&#xD;
             10% at the baseline visit.&#xD;
&#xD;
          6. Participant has previous exposure to systemic psoriasis therapy or phototherapy, but&#xD;
             not ideal.&#xD;
&#xD;
          7. Meet the following criteria for Tuberculosis screening: A. has no prior history of&#xD;
             occult or active tuberculosis. B. No signs or symptoms of active tuberculosis in&#xD;
             history and / or physical examination. C. in the first 6 weeks of the trial,&#xD;
             tuberculosis screening test meet the requirements of the trial.&#xD;
&#xD;
          8. Laboratory screening results:Hemoglobin≥110g/L.White blood cell≥4 * 109 /L.&#xD;
             Neutrophil≥1.5 * 109/L.Platelet≥100 * 109/L.Serum alanine aminotransferase and / or&#xD;
             aspartate aminotransferase not more than 1.5 times of the upper limit of normal.Serum&#xD;
             creatinine does not exceed 1.5 mg/dL (International units: ≤133 mol/L).&#xD;
&#xD;
          9. During the first 2 weeks of the study, Participant must stop adjuvant therapy&#xD;
             including traditional Chinese medicine and acupuncture.&#xD;
&#xD;
         10. Hepatitis B (HBV) screening in compliance with the requirements of this test.&#xD;
&#xD;
         11. Weight≥60Kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pustular, erythrodermic, and/or guttate forms of psoriasis.&#xD;
&#xD;
          2. Participant had treated with TNF antagonists within 6 weeks prior to the Baseline&#xD;
             visit.&#xD;
&#xD;
          3. Participant had treated with Other biological agents within 6 weeks prior to the&#xD;
             Baseline visit.&#xD;
&#xD;
          4. Participant had treated with Phototherapy or systemic antipsoriatic treatment (such&#xD;
             as:Methotrexate（MTX）， acitretin, cyclosporine, Total Glucosides of Paeony（TGP）,&#xD;
             treatment of psoriasis related Chinese medicines, etc.) and systemic corticosteroid&#xD;
             treatment within 4 weeks prior to the Baseline visit.&#xD;
&#xD;
          5. Participant had treated with Topical corticosteroid therapy, vitamin A or D analogue&#xD;
             or Anthralin within 2 weeks prior to the Baseline visit.&#xD;
&#xD;
          6. Participant received any drug that the drug's metabolism was less than 7 half lives&#xD;
             before the Baseline visit.&#xD;
&#xD;
          7. Participant plans to pregnant or breast feeding or father during the study.&#xD;
&#xD;
          8. The history of occult or active granuloma infections, including histoplasmosis,&#xD;
             coccidioidomycosis.&#xD;
&#xD;
          9. Participant has suffered from Non Mycobacterium tuberculosis infection or&#xD;
             opportunistic infections (such as cytomegalovirus sense of dyeing, Pneumocystis&#xD;
             carinii pneumonia, aspergillosis) within 6 weeks prior to the Baseline visit.&#xD;
&#xD;
         10. The close contact history of active tuberculosis patients or Tuberculosis screening&#xD;
             results do not meet the requirements.&#xD;
&#xD;
         11. Participant has suffered from severe infection (for example hepatitis, pneumonia,&#xD;
             acute pyelonephritis or sepsis), or participant use intravenous antibiotics now&#xD;
             because of infection within 6 weeks prior to the Baseline visit.&#xD;
&#xD;
         12. Participant has suffered from chronic or recurrent infections before or at present,&#xD;
             including (but not limited to) chronic kidney infection disease and chronic chest&#xD;
             infectious diseases (such as bronchial dilation), sinusitis, recurrent urinary tract&#xD;
             infections (such as recurrent pyelonephritis and chronic non remission cystitis),&#xD;
             open, overflow liquid or infection of skin wound or ulcer.&#xD;
&#xD;
         13. Human immunodeficiency virus (HIV) antibody positive.&#xD;
&#xD;
         14. Hepatitis B virus (HBV) screening results do not meet the requirements.&#xD;
&#xD;
         15. Hepatitis C virus (HCV) antibody positive.&#xD;
&#xD;
         16. Participant has demyelinating diseases such as multiple sclerosis or optic neuritis.&#xD;
&#xD;
         17. A history of congestive heart failure, including asymptomatic congestive heart&#xD;
             failure.&#xD;
&#xD;
         18. A history or sign of a lymph node hyperplasia, including lymphoma or suggestive of a&#xD;
             possible sign such as the size and location of an enlarged lymph node or a history of&#xD;
             clinically significant enlargement of the spleen.&#xD;
&#xD;
         19. Participant has symptoms or signs of severe, progressive or uncontrolled kidney,&#xD;
             liver, blood, gastrointestinal, endocrine, lung, heart, nerve, mental or brain&#xD;
             diseases.&#xD;
&#xD;
         20. There is a history of malignancy or previous history.&#xD;
&#xD;
         21. Joint prosthesis has not yet been removed or replaced.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhong Jin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongzhong Jin, M.D.</last_name>
    <phone>8613693583080</phone>
    <email>jinhongzhong@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhong Jin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Dermatology and Skin Disease Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heng Gu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Sun, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of The Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Gu, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005 Aug 15;175(4):2721-9.</citation>
    <PMID>16081850</PMID>
  </reference>
  <reference>
    <citation>Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007 Nov-Dec;25(6):535-46. Review.</citation>
    <PMID>18021890</PMID>
  </reference>
  <reference>
    <citation>Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998 Nov;139(5):846-50.</citation>
    <PMID>9892952</PMID>
  </reference>
  <results_reference>
    <citation>Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014-22.</citation>
    <PMID>14627786</PMID>
  </results_reference>
  <results_reference>
    <citation>Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014 Apr 17;8:169-82. doi: 10.2147/BTT.S41481. eCollection 2014. Review.</citation>
    <PMID>24790410</PMID>
  </results_reference>
  <results_reference>
    <citation>Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 Jun;152(6):1304-12.</citation>
    <PMID>15948997</PMID>
  </results_reference>
  <results_reference>
    <citation>Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010 Feb 2;340:c147. doi: 10.1136/bmj.c147.</citation>
    <PMID>20124563</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiu HY, Wang TS, Cho YT, Tsai TF. Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol. 2013 Jun;52(6):673-80. doi: 10.1111/j.1365-4632.2011.05273.x. Epub 2012 Feb 20.</citation>
    <PMID>22348620</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>February 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Skin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

